Top Industry Leaders in the Churg Strauss Syndrome Market
Latest Churg Strauss Syndrome Companies Update:
Apheresis Technologies (APT) initiates a Phase 2 study to evaluate the effectiveness of double filtration plasmapheresis (DFPP) in treating active CSS. DFPP offers a targeted approach to remove harmful immune complexes from the blood, potentially improving outcomes. (Oct 20, 2023)
Researchers at Brigham and Women's Hospital identify a potential biomarker for predicting disease flare-ups in CSS patients. This biomarker could inform treatment decisions and improve disease management. (Dec 15, 2023)
Clinical trials investigating the use of targeted therapies like rituximab and methotrexate in combination with traditional corticosteroids for CSS treatment are ongoing. These studies aim to optimize existing treatment strategies and improve patient response. (Jan 23, 2024)
List of Churg Strauss Syndrome Key companies in the market
- livergate
- Heron Therapeutics, Inc.
- IRX Therapeutics, Inc.
- Brabourne Enterprises Ltd
- Rupus Research Alliance
- Tianjin Tianyao Pharmaceuticals Co., Ltd
- Grifols, S.A